Bare Metal Bifurcation Stent Clinical Trial in Humans

General Inclusion Criteria * Candidate for percutaneous coronary intervention \& emergent coronary artery bypass graft surgery * Clinical evidence of ischemic heart disease or a positive functional study * Female patients of childbearing potential has negative pregnancy test within 7 days before trial procedure * Patient or patient's legal representative provided written informed consent * Patient agrees to comply with follow-up evaluations Angiographic Inclusion Criteria * Target lesion ia a single de novo bifurcation lesion involving a native coronary artery with reference vessel diameter for the proximal main of 3.8 - 4.3 mm, distal main of 3.0 - 3.5 mm, \& side branch RVD up to 2.5 mm * Acceptable target lesion lengths are any combination of: * \<16mm proximally from carina in proximal main vessel * \<16mm distally from the carina in distal main branch * \<12mm from carina in side branch * Target lesion in main vessel has stenosis of \> 50% and \<100% * Target vessel has (TIMI) flow \>2 General Exclusion Criteria * Known hypersensitivity/contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum, or sensitivity to contrast media, which can't be adequately pre-medicated * Platelet count \<100,000 cells/mm³ or \>700,000 cells/mm³, or a white blood cell (WBC) count \<3,000 cells/mm³ within 7 days prior to index procedure * Serum creatinine level \>170 micromol/L within 7 days prior to index procedure * Evidence of acute MI within 72 hours of intended trial procedure (defined as: QWMI or NQWMI having CK enzymes \>2X laboratory upper limit of normal with presence of elevated CK-MB (any amount above laboratory upper limit of normal) * Previous stenting anywhere in target vessel * PCI of non-target vessel within 30 days prior to procedure that results in any MACE event. If non target vessel stent is implanted within 72 hours prior to index procedure, 2 post procedural serial CK or CK-MB measurements must be below investigational site's upper limit of normal. * PCI of non-target vessel within 24 hours prior to procedure * Planned PCI of any vessel within 30 days post-procedure * Planned PCI of the target vessel within 6 months post-procedure * During index procedure, target lesion requires treatment with device other than PTCA or cutting balloon prior to stent placement * Documented left ventricular ejection fraction (LVEF) \<30% at most recent evaluation. * History of stroke or transient ischemic attack (TIA) within prior 6 months * Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months * History of bleeding diathesis or coagulopathy or will refuse blood transfusions * Concurrent medical condition with life expectancy \< 12 months * Currently participating in investigational drug or device trial that's not completed the primary endpoint or that clinically interferes with current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures. Angiographic Exclusion Criteria * Bifurcation angle of \>90 degrees by visual estimate * Target lesion located in native vessel with saphenous vein graft or left/right internal mammary artery (LIMA/RIMA) bypass * Significant stenosis (\>50%) proximal or distal to target lesion that might require revascularization or impede run off. * Target vessel is excessively tortuous (two bends \>90º to reach target lesion) * Target lesion has any of following characteristics: * Lesion location is aorto-ostial, unprotected left main lesion, or within 5 mm of origin of left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA). * Severely calcified * Evidence of thrombus * Co-existence of unprotected left main coronary artery disease (obstruction \>50% in left main coronary artery)